Overview
NAD(P)HX epimerase deficiency is a rare metabolic disorder affecting the redox balance by impairing the interconversion of NAD(P)H isomers, leading to cellular dysfunction and potentially severe clinical manifestations 3.Diagnosis
Elevated levels of specific NAD(P)H isomers in biological samples 3.
Genetic testing identifying mutations in the NAD(P)HX epimerase gene 3.
Clinical correlation with symptoms indicative of redox imbalance 3.Management
No specific drug treatments mentioned in the provided abstracts; focus on supportive care 3.
Monitoring and managing symptoms related to cellular energy deficits 3.
Consideration of dietary modifications to support metabolic pathways 3.Special Populations
Limited data in abstracts regarding specific management adjustments for pregnancy, pediatrics, or elderly patients 3.
Comorbidities may exacerbate symptoms; individualized care plans recommended 3.Key Recommendations
Genetic testing is essential for confirming NAD(P)HX epimerase deficiency diagnosis (Evidence: Moderate 3).
Supportive care measures should be tailored to manage symptoms arising from redox imbalance (Evidence: Expert opinion 3).
Regular monitoring of metabolic markers is crucial for assessing disease progression and response to management (Evidence: Moderate 3).References
1 Narne P, Phanithi PB. Role of NAD. Cellular and molecular neurobiology 2023. link
2 Kennedy BE, Sadek M, Elnenaei MO, Reiman A, Gujar SA. Targeting NAD. Trends in cancer 2020. link
3 Zhang M, Ying W. NAD. Antioxidants & redox signaling 2019. link
4 Huang Q, Sun M, Li M, Zhang D, Han F, Wu JC et al.. Combination of NAD. Molecular neurobiology 2018. link